Axsome Therapeutics, Inc.
AXSM · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -1.03 | -1.79 | -0.47 | -0.41 |
| FCF Yield | -3.17% | -4.03% | -3.74% | -7.64% |
| EV / EBITDA | -14.42 | -15.18 | -17.39 | -11.21 |
| Quality | ||||
| ROIC | -81.71% | -51.65% | -79.26% | -190.86% |
| Gross Margin | 91.37% | 90.37% | 89.61% | 0.00% |
| Cash Conversion Ratio | 0.45 | 0.61 | 0.62 | 0.83 |
| Growth | ||||
| Revenue 3-Year CAGR | 97.54% | – | – | – |
| Free Cash Flow Growth | 11.66% | -24.27% | -8.00% | -38.25% |
| Safety | ||||
| Net Debt / EBITDA | 0.45 | 0.89 | 0.61 | 0.30 |
| Interest Coverage | -42.71 | -35.93 | -24.06 | -21.89 |
| Efficiency | ||||
| Inventory Turnover | 2.12 | 1.72 | 1.20 | 0.00 |
| Cash Conversion Cycle | -482.28 | -229.81 | -2,132.66 | -4,153.03 |